Toumi’s appointment is effective from June 17, 2024, with no fixed tenure, as stated in Lupin’s press release. He brings over 20 years of experience in the biotech, pharma, and CDMO sectors, having worked across Europe, North America, and Asia. He holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.
Toumi previously served as Chief Business Officer at KBI Biopharma, Vice President and Head of mRNA Business & New Ventures at Catalent Pharma Solutions, and held significant roles at Merck Group and Bayer Technology Services.
Lupin, an innovation-driven transnational pharmaceutical company, specializes in the development and commercialization of branded and generic formulations, biotechnology products, and APIs. With operations in over 100 markets, Lupin has a significant presence in the U.S., India, South Africa, the Asia Pacific (APAC) region, Latin America (LATAM), Europe, and the Middle East.
 of its new subsidiary, Lupin Manufacturing Solutions (LMS). LMS focuses on the development, manufacturing, and sales of active pharmaceutical ingredients (APIs) and is also establishing its contract development and manufacturing operations (CDMO) business.){kind=link}